1.         Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Aokage K, Saji H, Watanabe SI; Japan Clinical Oncology Group Lung Cancer Surgical Study Group. Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 Apr;161(4):1469-1480. doi: 10.1016/j.jtcvs.2020.01.107. Epub 2020 Apr 6.

2.         Tsutani Y, Nakayama H, Ito H, Handa Y, Mimae T, Miyata Y, Okada M. Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography. Clin Lung Cancer. 2021 May;22(3):e431-e437. doi: 10.1016/j.cllc.2020.06.013. Epub 2020 Jun 19.

3.         Okada M. Commentary: Aspects of epidermal growth factor receptor status: Prognostic factor versus predictive factor. J Thorac Cardiovasc Surg. 2021 Sep;162(3):678-679. doi: 10.1016/j.jtcvs.2020.07.085. Epub 2020 Aug 3.

4.         Kagimoto A, Tsutani Y, Handa Y, Mimae T, Miyata Y, Okada M. Patient Selection of Sublobar Resection Using Visual Evaluation of Positron-Emission Tomography (PET) for Early-Stage Lung Adenocarcinoma. Ann Surg Oncol. 2021 Apr;28(4):2068-2075. doi: 10.1245/s10434-020-09150-w. Epub 2020 Sep 18.

5.         Kagimoto A, Tsutani Y, Okada M. ASO Author Reflections: Usefulness of Visual Evaluation of PET in Predicting Prognosis after Lung Resection for Early-Stage Lung Adenocarcinoma and Selecting Candidates for Sublobar Resection. Ann Surg Oncol. 2021 Apr;28(4):2076-2077. doi: 10.1245/s10434-020-09162-6. Epub 2020 Sep 23.

6.         Kagimoto A, Tsutani Y, Handa Y, Mimae T, Miyata Y, Okada M. Prediction of Acute Exacerbation of Interstitial Pneumonia Using Visual Evaluation of PET. Ann Thorac Surg. 2021 Jul;112(1):264-270. doi: 10.1016/j.athoracsur.2020.08.018. Epub 2020 Oct 12.

7.         Kagimoto A, Tsutani Y, Kushitani K, Kai Y, Kambara T, Miyata Y, Takeshima Y, Okada M. Segmentectomy vs Lobectomy for Clinical Stage IA Lung Adenocarcinoma With Spread Through Air Spaces. Ann Thorac Surg. 2021 Sep;112(3):935-943. doi: 10.1016/j.athoracsur.2020.09.020. Epub 2020 Nov 2.

8.         Kimura Y, Sasada S, Emi A, Masumoto N, Kadoya T, Okada M. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer. Support Care Cancer. 2021 Jul;29(7):3507-3512. doi: 10.1007/s00520-020-05868-1. Epub 2020 Nov 4. 

9.         Tsutani Y, Handa Y, Shimada Y, Ito H, Ikeda N, Nakayama H, Yoshimura K, Okada M. Comparison of cancer control between segmentectomy and wedge resection in patients with clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 Oct;162(4):1244-1252.e1. doi: 10.1016/j.jtcvs.2020.10.024. Epub 2020 Oct 22.

10.     Shimizu K, Ohtaki Y, Suzuki K, Date H, Yamashita M, Iizasa T, Ito H, Yoshimura K, Okada M, Chida M; Japanese Association for Chest Surgery. Salvage Surgery for Non-Small Cell Lung Cancer After Definitive Radiotherapy. Ann Thorac Surg. 2021 Sep;112(3):862-873. doi: 10.1016/j.athoracsur.2020.10.035. Epub 2020 Nov 26.

11.     Kamigaichi A, Tsutani Y, Okada M. Reply to Zhang et al. Eur J Cardiothorac Surg. 2021 Apr 29;59(4):928. doi: 10.1093/ejcts/ezaa419.

12.     Sueoka S, Sasada S, Masumoto N, Emi A, Kadoya T, Okada M. Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer. Breast Cancer Res Treat. 2021 May;187(1):125-133. doi: 10.1007/s10549-020-06088-1. Epub 2021 Jan 23.

13.     Miyazaki T, Fukuchi E, Yamamoto H, Miyata H, Tanaka F, Okada M, Suzuki K, Yoshino I, Endo S, Sato Y, Chida M, Nagayasu T. Certified thoracic surgeons in Japan: a national database survey on risk-adjusted mortality associated with lung resection. Surg Today. 2021 Aug;51(8):1268-1275. doi: 10.1007/s00595-021-02227-3. Epub 2021 Jan 30.

14.     Sasada S, Kimura Y, Masumoto N, Emi A, Kadoya T, Arihiro K, Okada M. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. Eur J Surg Oncol. 2021 Jul;47(7):1588-1592. doi: 10.1016/j.ejso.2021.02.026. Epub 2021 Mar 3.

15.     Sasada S, Masumoto N, Emi A, Kadoya T, Arihiro K, Okada M. Clinical effect of the pathological axillary assessment method in breast cancer without clinical nodal metastasis. Breast Cancer. 2021 Sep;28(5):1016-1022. doi: 10.1007/s12282-021-01236-x. Epub 2021 Mar 19.

16.     Mimae T, Saji H, Okada M. ASO Author Reflections: Is Wedge Resection Optimal for Octogenarians with Early-Stage Non-Small-Cell Lung Cancer Compared with Lobectomy/Segmentectomy?Ann Surg Oncol. 2021 Nov;28(12):7228-7229. doi: 10.1245/s10434-021-09860-9. Epub 2021 Mar 23. 

17.     Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.

18.     Ueda D, Ito M, Tsutani Y, Giménez-Capitán A, Román-Lladó R, Pérez-Rosado A, Aguado C, Kushitani K, Miyata Y, Arihiro K, Molina-Vila MA, Rosell R, Takeshima Y, Okada M. Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. J Cancer Res Clin Oncol. 2021 Dec;147(12):3709-3718. doi: 10.1007/s00432-021-03609-3. Epub 2021 Apr 1.

19.     Hirohata R, Hamai Y, Emi M, Kurokawa T, Yoshikawa T, Ohsawa M, Tadokoro K, Okada M. Prediction of the tumor response and survival based on computed tomography in esophageal squamous cell carcinoma after trimodality therapy. Surg Today. 2021 Sep;51(9):1496-1505. doi: 10.1007/s00595-021-02277-7. Epub 2021 Apr 2.

20.     Futamura M, Oba M, Masuda N, Bando H, Okada M, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Ohno S. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). Breast Cancer. 2021 Sep;28(5):1023-1037. doi: 10.1007/s12282-021-01238-9. Epub 2021 Apr 3.

21.     Mimae T, Saji H, Nakamura H, Okumura N, Tsuchida M, Sonobe M, Miyazaki T, Aokage K, Nakao M, Haruki T, Okada M, Suzuki K, Chida M. Survival of Octogenarians with Early-Stage Non-small Cell Lung Cancer is Comparable Between Wedge Resection and Lobectomy/Segmentectomy: JACS1303. Ann Surg Oncol. 2021 Nov;28(12):7219-7227. doi: 10.1245/s10434-021-09835-w. Epub 2021 Apr 26.

22.     Hashimoto M, Yamamoto H, Endo S, Okada M, Miyata H, Hasegawa S, Chida M. Japanese Current Status of Curative-Intent Surgery for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 Apr;113(4):1348-1353. doi: 10.1016/j.athoracsur.2021.04.042. Epub 2021 Apr 27.

23.     Handa Y, Tsutani Y, Okada M. Transition of Treatment for Ground Glass Opacity-Dominant Non-Small Cell Lung Cancer. Front Oncol. 2021 Apr 15;11:655651. doi: 10.3389/fonc.2021.655651. eCollection 2021.

24.     Yamaguchi K, Nakao S, Iwamoto H, Kagimoto A, Handa Y, Sakamoto S, Horimasu Y, Masuda T, Mimae T, Miyamoto S, Nakashima T, Tsutani Y, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients. Sci Rep. 2021 May 12;11(1):10105. doi: 10.1038/s41598-021-89663-w.

25.     Shintani Y, Yamamoto H, Sato Y, Shimizu K, Endo S, Okada M, Suzuki K, Fukuchi E, Miyata H, Chida M. A risk model for prolonged air leak after lobectomy using the National Clinical Database in Japan. Surg Today. 2022 Jan;52(1):69-74. doi: 10.1007/s00595-021-02300-x. Epub 2021 May 17.

26.     Tsutani Y, Kagimoto A, Handa Y, Mimae T, Miyata Y, Okada M. Prognostic role of interstitial pneumonia with or without emphysema in patients with clinical stage I lung cancer. Jpn J Clin Oncol. 2021 Jul 1;51(7):1123-1131. doi: 10.1093/jjco/hyab073.

27.     Handa Y, Tsutani Y, Mimae T, Miyata Y, Ito H, Shimada Y, Nakayama H, Ikeda N, Okada M. Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer. Ann Thorac Surg. 2022 Apr;113(4):1317-1324. doi: 10.1016/j.athoracsur.2021.04.083. Epub 2021 May 20.

28.     Hamada A, Soh J, Hata A, Nakamatsu K, Shimokawa M, Yatabe Y, Oizumi H, Tsuboi M, Horinouchi H, Yoshino I, Tanahashi M, Toyooka S, Okada M, Yokomise H, Yamashita M, Nishimura Y, Yamamoto N, Nakagawa K, Mitsudomi T. Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clin Lung Cancer. 2021 Nov;22(6):596-600. doi: 10.1016/j.cllc.2021.04.006. Epub 2021 Apr 27.

29.     Amioka A, Kadoya T, Sueoka S, Kobayashi Y, Sasada S, Emi A, Masumoto N, Ito M, Nakayama K, Okada M. Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer. Breast Cancer. 2021 Sep;28(5):1062-1071. doi: 10.1007/s12282-021-01241-0. Epub 2021 May 28.

30.     Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M, Brun P, Dupont C, Branden E, Rossi G, Schrock A, Ali S, Gounant V, Magne F, Blum TG, Schram AM, Monnet I, Shih JY, Sabari J, Pérol M, Zhu VW, Nagasaka M, Doebele R, Camidge DR, Arcila M, Ou SI, Moro-Sibilot D, Rosell R, Muscarella LA, Liu SV, Cadranel J. Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021 Sep 1;39(25):2791-2802. doi: 10.1200/JCO.20.03307. Epub 2021 Jun 2.

31.     Kagimoto A, Tsutani Y, Kushitani K, Kambara T, Mimae T, Miyata Y, Takeshima Y, Okada M. Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer. BMC Pulm Med. 2021 Jun 2;21(1):186. doi: 10.1186/s12890-021-01554-y.

32.     Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M, Kitasaki N, Okada M. Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy. Anticancer Res. 2021 Jun;41(6):3011-3021. doi: 10.21873/anticanres.15083.

33.     Sato T, Shimada Y, Mimae T, Tsutani Y, Miyata Y, Ito H, Nakayama H, Okada M, Ikeda N. The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study. Lung Cancer. 2021 Aug;158:9-14. doi: 10.1016/j.lungcan.2021.05.029. Epub 2021 May 29.

34.     Nakao S, Yamaguchi K, Iwamoto H, Kagimoto A, Mimae T, Tsutani Y, Miyata Y, Hamada H, Okada M, Hattori N. Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury. Ann Thorac Surg. 2022 May;113(5):1617-1623. doi: 10.1016/j.athoracsur.2021.05.059. Epub 2021 Jun 15.

35.     Tsutani Y, Shimada Y, Ito H, Miyata Y, Ikeda N, Nakayama H, Okada M. Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer. Front Oncol. 2021 Jun 7;11:622742. doi: 10.3389/fonc.2021.622742. eCollection 2021.

36.     Amioka A, Kadoya T, Sueoka S, Kobayashi Y, Sasada S, Emi A, Masumoto N, Ito M, Nakayama K, Okada M. Correction to: Effect of Wnt5a on drug resistance in estrogen receptor‑positive breast cancer. Breast Cancer. 2021 Sep;28(5):1072. doi: 10.1007/s12282-021-01268-3.

37.     Tsutani Y, Imai K, Ito H, Miyata Y, Ikeda N, Nakayama H, Okada M. Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg. 2022 May;113(5):1608-1616. doi: 10.1016/j.athoracsur.2021.04.108. Epub 2021 Jun 26.

38.     Yamaoka K, Kawaoka T, Aikata H, Ando Y, Kosaka Y, Suehiro Y, Fujii Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Saeki Y, Kuroda S, Kobayashi T, Ohdan H, Miyata Y, Okada M, Chayama K. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. Intern Med. 2021;60(13):2047-2053. doi: 10.2169/internalmedicine.5870-20. Epub 2021 Jul 1.

39.     Ito M, Miyata Y, Hirano S, Irisuna F, Kushitani K, Kai Y, Kishi N, Tsutani Y, Takeshima Y, Okada M. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma. J Cancer Res Clin Oncol. 2022 Jun;148(6):1419-1428. doi: 10.1007/s00432-021-03721-4. Epub 2021 Jul 3.

40.     Handa Y, Tsutani Y, Mimae T, Miyata Y, Ito H, Shimada Y, Nakayama H, Ikeda N, Okada M. Systematic Versus Lobe-Specific Mediastinal Lymphadenectomy for Hypermetabolic Lung Cancer. Ann Surg Oncol. 2021 Nov;28(12):7162-7171. doi: 10.1245/s10434-021-10020-2. Epub 2021 Jul 3.

41.     Handa Y, Tsutani Y, Mimae T, Miyata Y, Okada M. Postoperative Pulmonary Function After Complex Segmentectomy. Ann Surg Oncol. 2021 Dec;28(13):8347-8355. doi: 10.1245/s10434-021-09828-9. Epub 2021 Jul 22.

42.     Handa Y, Tsutani Y, Okada M. ASO Author Reflection: Position of the Complex Segmentectomy on Postoperative Pulmonary Function. Ann Surg Oncol. 2021 Dec;28(13):8356-8357. doi: 10.1245/s10434-021-09847-6. Epub 2021 Jul 23.

43.     Handa Y, Tsutani Y, Ito M, Miyata Y, Mukaida H, Kaneko M, Takeshima Y, Okada M. Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine Carcinoma. Clin Lung Cancer. 2022 Jan;23(1):e9-e16.e1. doi: 10.1016/j.cllc.2021.06.010. Epub 2021 Jul 4.

44.     Mimae T, Miyata Y, Yoshimura K, Tsutani Y, Imai K, Ito H, Nakayama H, Ikeda N, Okada M. Risk of death due to other causes is lower among octogenarians with non-small cell lung cancer after wedge resection than lobectomy/segmentectomy. Jpn J Clin Oncol. 2021 Oct 5;51(10):1561-1569. doi: 10.1093/jjco/hyab122.

45.     Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M, Ueno M, Nakagawa S, Takagi M, Tsunoda S, Abe T, Nakamura T, Okada M, Toh Y, Shibuya Y, Yamamoto S, Katayama H, Nakamura K, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 2021 Dec;161(6):1878-1886.e2. doi: 10.1053/j.gastro.2021.08.007. Epub 2021 Aug 10.

46.     Hasegawa S, Yokoi K, Okada M, Tanaka F, Shimokawa M, Daimon T, Nakano T. Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2022 Jun;163(6):1940-1947.e5. doi: 10.1016/j.jtcvs.2021.07.017. Epub 2021 Jul 17.

47.     Samejima J, Ito H, Nagashima T, Nemoto D, Eriguchi D, Nakayama H, Ikeda N, Okada M. Anatomical location and number of metastatic lymph nodes for prognosis of non-small cell lung cancer. J Thorac Dis. 2021 Jul;13(7):4083-4093. doi: 10.21037/jtd-21-390.

48.     Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26.

49.     Handa Y, Tsutani Y, Okada M. ASO Author Reflections: Survival Outcomes between Patients with Hypermetabolic Non-small Cell Lung Cancer Undergoing Systematic and Lobe-Specific Mediastinal Lymph Node Dissection. Ann Surg Oncol. 2021 Nov;28(12):7172. doi: 10.1245/s10434-021-10037-7. Epub 2021 Sep 3. 

50.     Nakagawa K, Kijima T, Okada M, Morise M, Kato M, Hirano K, Fujimoto N, Takenoyama M, Yokouchi H, Ohe Y, Hida T, Aoe K, Kishimoto T, Hirokawa M, Matsuki H, Kaneko Y, Yamada T, Morimoto C, Takeda M. Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma. JTO Clin Res Rep. 2021 Apr 29;2(6):100178. doi: 10.1016/j.jtocrr.2021.100178. eCollection 2021 Jun.

51.     Handa Y, Tsutani Y, Okada M. Reply to "Lobe-Specific Lymph Node Dissection for Lung Cancer: Is It Still Feasible?" by Han-Yu Deng. Ann Surg Oncol. 2021 Dec;28(Suppl 3):848-849. doi: 10.1245/s10434-021-10684-w. Epub 2021 Oct 9.

52.     Ito M, Miyata Y, Kushitani K, Kagimoto A, Ueda D, Tsutani Y, Takeshima Y, Okada M. Pathological high malignant grade is higher risk of recurrence in pN0M0 invasive lung adenocarcinoma, even with small invasive size. Thorac Cancer. 2021 Dec;12(23):3141-3149. doi: 10.1111/1759-7714.14163. Epub 2021 Oct 12.

53.     Nakao M, Saji H, Mun M, Nakamura H, Okumura N, Tsuchida M, Sonobe M, Miyazaki T, Aokage K, Haruki T, Okada M, Suzuki K, Chida M. Prognostic Impact of Mediastinal Lymph Node Dissection in Octogenarians With Lung Cancer: JACS1303. Clin Lung Cancer. 2022 May;23(3):e176-e184. doi: 10.1016/j.cllc.2021.09.007. Epub 2021 Sep 24.

54.     Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S, Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M, Yoshino I, Nakagawa K; West Japan Oncology Group. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). J Clin Oncol. 2022 Jan 20;40(3):231-241. doi: 10.1200/JCO.21.01729. Epub 2021 Nov 2.

55.     Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol. 2022 Jan 10;40(2):180-188. doi: 10.1200/JCO.21.01315. Epub 2021 Nov 18.

56.     Hamai Y, Hihara J, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M, Kitasaki N, Okada M. Prospective Randomized Trial of Early Postoperative Enteral and Total Parenteral Nutrition for Treating Esophageal Cancer. Anticancer Res. 2021 Dec;41(12):6237-6246. doi: 10.21873/anticanres.15444.

57.     Kagimoto A, Tsutani Y, Okada M. Segmentectomy for STAS positive lung adenocarcinoma. Ann Thorac Surg. 2021 Dec 20:S0003-4975(21)02123-8. doi: 10.1016/j.athoracsur.2021.11.039. Online ahead of print.

58.     Takamochi K, Suzuki K, Tsuboi M, Niho S, Ishikura S, Oyamada S, Yamaguchi T, Okada M; Advanced Clinical Trial Chest Surgery Group. Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 Dec 9:S0022-5223(21)01714-1. doi: 10.1016/j.jtcvs.2021.11.079. Online ahead of print.

59.     Fukui K, Masumoto N, Yokoyama E, Kanou A, Yokozaki M, Sasada S, Emi A, Kadoya T, Arihiro K, Okada M. Ultrasonography Combined With Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer. Cancer Diagn Progn. 2021 Jul 3;1(4):309-316. doi: 10.21873/cdp.10041. eCollection 2021 Sep-Oct. 

60.     Kimura Y, Sasada S, Emi A, Masumoto N, Kadoya T, Okada M. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer. Support Care Cancer. 2021 Jul;29(7):3507-3512. doi: 10.1007/s00520-020-05868-1. Epub 2020 Nov 4

61.     Tanaka K, Masuda N, Hayashi N, Sagara Y, Hara F, Kadoya T, Matsui A, Miyazaki C, Shien T, Tokunaga E, Hayashi T, Niikura N, Maeda S, Komoike Y, Bando H, Kanbayashi C, Iwata H. Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study. Breast Cancer. 2021 Jul;28(4):896-903. doi: 10.1007/s12282-021-01225-0. Epub 2021 Feb 18.

62.     Sasada S, Kimura Y, Masumoto N, Emi A, Kadoya T, Arihiro K, Okada M. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. Eur J Surg Oncol. 2021 Jul;47(7):1588-1592. doi: 10.1016/j.ejso.2021.02.026. Epub 2021 Mar 3.

63.     Sasada S, Masumoto N, Emi A, Kadoya T, Arihiro K, Okada M. Clinical effect of the pathological axillary assessment method in breast cancer without clinical nodal metastasis. Breast Cancer. 2021 Sep;28(5):1016-1022. doi: 10.1007/s12282-021-01236-x. Epub 2021 Mar 19.

64.     Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial. Breast Cancer Res Treat. 2021 Jul;188(1):117-131. doi: 10.1007/s10549-021-06184-w. Epub 2021 Mar 25.

65.     Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, Tsuda H, Yamamoto Y, Aogi K, Kubo M, Tamura K, Hayashi N, Miyashita M, Kadoya T, Saji S, Toi M, Imoto S, Jinno H. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer. 2022 Jan;29(1):1-8. doi: 10.1007/s12282-021-01307-z. Epub 2021 Oct 19.

66.     Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M, Kitasaki N, Okada M. Comparison of open and thoracoscopic esophagectomy in patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy. Anticancer Res 41: 3011-3021, 2021.

67.     Tanaka Y, Takeuchi H, Nakashima Y, Nagano H, Ueno T, Tomizuka K, Morita S, Emi Y, Hamai Y, Hihara J, Saeki H, Oki E, Kunisaki C, Otsuji E, Baba H, Matsubara H, Maehara Y, Kitagawa Y, Yoshida K. Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5). ESMO Open 6: 100277, 2021. 

68.     Hamai Y, Hihara J, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M, Kitasaki N, Okada M. Prospective randomized trial of early postoperative enteral and total parenteral nutrition for treating esophageal cancer. Anticancer Res 41: 6237-6246, 2021.

69.     Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda N, Nakayama H, Okada M. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022 Jan 26:S0022-5223(22)00097-6. doi: 10.1016/j.jtcvs.2022.01.025. Online ahead of print.

70.     Kawamata A, Sasada S, Emi A, Masumoto N, Kadoya T. Monitoring of programmed cell death ligand-1 blockade using FDG PET/CT for microsatellite instability-high metastatic breast cancer. Clin Nucl Med 47: e252-253, 2022.

71.     Sasada S, Kai A, Kimura Y, Masumoto N, Kadoya T. Four patterns of abnormal ring-like uptakes on dedicated breast PET. Clin Nucl Med 47: e192-e193, 2022.

72.     Sasada S, Masumoto N, Emi A, Kadoya T, Okada M. Malignant prediction of incidental findings using ring-type dedicated breast positron emission tomography. Sci Rep 12: 1144, 2022.

73.     Hara T, Kitagawa H, Kajihara T, Koba Y, Tadera K, Nagaoka R, Ota S, Nakaoka Y, Nomura T, Omori K, Shigemoto N, Sasada S, Ota K, Kashiyama S, Yokozaki M, Shime N, Ohge H. Bloodstream Infection Caused by Actinomyces neuii subsp. anitratus in a Patient with Breast Cancer: A Case Report and Literature Review. Hiroshima J Med Sci 70: 43-47, 2021.

74.     Mimae T, Miyata Y, Kumada T, Handa Y, Tsutani Y, Okada M.: Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function. Interact Cardiovasc Thorac Surg. 2022 online ahead of print.

75.     Kawamoto N, Okita R, Hayashi M, Okada M, Ito K, Ikeda E, Inokawa H. Suspected fibrin glue-induced acute eosinophilic pneumonia after pulmonary resection: A case report. Thorac Cancer 12: 2126-2129, 2021.

76.     Kawamoto N, Okita R, Okada M, Ito K, Hirazawa K, Inokawa H. Fibrin glue-induced eosinophilic pleural effusion after pulmonary resection: A case report. Int J Surg Case Rep 85: 106239, 2021.

77.     Kawamoto N, Okita R, Hayashi M, Osoreda H, Inokawa H, Murakami T. Clinicopathological feature of a resected large mixed squamous cell and glandular papilloma: A case report. Int J Surg Case Rep 93: 106956, 2022.

78.     Kimura Y1), Masumoto N1), Kanou A2), Fukui K2), Sasada S1), Emi A1), Kadoya T1), Arihiro K3), Okada M.1) (1) Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 2) Division of Laboratory Medicine, Hiroshima University Hospital, 3) Department of Anatomical Pathology, Hiroshima University Hospital ): The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer. Supportive Care in Cancer, Surgical Oncology 41; 101725, Online ahead of print, 2021.

79.     Kagimoto A, Tsutani Y, Mimae T, Miyata Y, Okada M. Segmentectomy vs. lobectomy for solid predominant cN0 lung cancer: analysis using visual evaluation of PET. European Journal of Cardio-Thoracic Surgery. 2022; 61: 279–286.

80.     Kagimoto A, Tsutani Y, Shimada Y, Mimae T, Miyata Y, Ito H, Nakayama H, Ikeda N, Okada M. Oncological Outcome of Segmentectomy for Early-Stage NSCLC with Invasive Characteristics: A multicenter Study. European Journal of Cardio-Thoracic Surgery. 2022, [epub ahead of print] doi: 10.1093/ejcts/ezac055.

81.     Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Kitasaki N, Okada M. Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma. Anticancer Res 42(3): 1499-1507, 2022.

82.     Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Shimada Y, Ito H, Nakayama H, Ikeda N, Okada M. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2022 published online ahead of print.

83.     木村優里1，2)，舛本法生1)，福井佳与1)等 (1) 広島大学病院　乳腺外科，2) 呉医療センター・中国がんセンター　乳腺外科，3) 広島大学病院診療支援部)：高度のTILs を伴う乳癌（LPBC）を超音波画像で予測できるのか？. 乳腺甲状腺超音波医学 vol 10. No3. 33-36，2021.

84.     甲斐あずさ，藤﨑成至1)，石川聖1)，高畑明寛1)，難波洋介1)，福田敏勝(1)中国労災病院　外科)：外傷性肋骨骨折による遅発性胸部大動脈損傷の1例．日本臨床外科学会雑誌82(12)：2136-2140，2021.